MedTrace Logo

Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

NCT04862858 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4197

Last updated 2022-05-20

No results posted yet for this study

Summary

This is an educational outreach to patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) and their primary care and specialist providers to improve use of guideline-recommended treatments, specifically sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.

Conditions

Interventions

OTHER

Educational Intervention

The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Humana Healthcare Research, Inc.

    collaborator UNKNOWN

  • Humana Inc.

    lead INDUSTRY

Principal Investigators

  • Alexjandro Daviano, DN, DrPH · Humana Inc.

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2021-11-30
Completion
2022-08-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04862858 on ClinicalTrials.gov